vs
REPLIGEN CORP（RGEN）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是STURM RUGER & CO INC的1.3倍（$197.9M vs $151.1M），REPLIGEN CORP同比增速更快（13.6% vs 3.6%），REPLIGEN CORP自由现金流更多（$17.6M vs $12.3M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 5.1%）
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
RGEN vs RGR — 直观对比
营收规模更大
RGEN
是对方的1.3倍
$151.1M
营收增速更快
RGEN
高出10.0%
3.6%
自由现金流更多
RGEN
多$5.2M
$12.3M
两年增速更快
RGEN
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.9M | $151.1M |
| 净利润 | $13.3M | — |
| 毛利率 | 52.5% | 17.8% |
| 营业利润率 | 9.0% | 2.3% |
| 净利率 | 6.7% | — |
| 营收同比 | 13.6% | 3.6% |
| 净利润同比 | 143.9% | — |
| 每股收益（稀释后） | $0.24 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGENRGR
| Q4 25 | $197.9M | $151.1M | ||
| Q3 25 | $188.8M | $126.8M | ||
| Q2 25 | $182.4M | $132.5M | ||
| Q1 25 | $169.2M | $135.7M | ||
| Q4 24 | $174.1M | $145.8M | ||
| Q3 24 | $154.9M | $122.3M | ||
| Q2 24 | $154.1M | $130.8M | ||
| Q1 24 | $151.3M | $136.8M |
净利润RGENRGR
| Q4 25 | $13.3M | — | ||
| Q3 25 | $14.9M | $1.6M | ||
| Q2 25 | $14.9M | $-17.2M | ||
| Q1 25 | $5.8M | $7.8M | ||
| Q4 24 | $-30.3M | — | ||
| Q3 24 | $-654.0K | $4.7M | ||
| Q2 24 | $3.3M | $8.3M | ||
| Q1 24 | $2.1M | $7.1M |
毛利率RGENRGR
| Q4 25 | 52.5% | 17.8% | ||
| Q3 25 | 53.2% | 15.1% | ||
| Q2 25 | 50.0% | 3.9% | ||
| Q1 25 | 53.6% | 22.0% | ||
| Q4 24 | 26.1% | 22.8% | ||
| Q3 24 | 50.0% | 18.5% | ||
| Q2 24 | 49.8% | 22.3% | ||
| Q1 24 | 49.5% | 21.5% |
营业利润率RGENRGR
| Q4 25 | 9.0% | 2.3% | ||
| Q3 25 | 8.9% | -2.7% | ||
| Q2 25 | 7.6% | -15.6% | ||
| Q1 25 | 3.9% | 6.2% | ||
| Q4 24 | -17.7% | 7.8% | ||
| Q3 24 | -5.1% | 3.1% | ||
| Q2 24 | 1.0% | 6.9% | ||
| Q1 24 | 1.3% | 5.5% |
净利率RGENRGR
| Q4 25 | 6.7% | — | ||
| Q3 25 | 7.9% | 1.2% | ||
| Q2 25 | 8.2% | -13.0% | ||
| Q1 25 | 3.4% | 5.7% | ||
| Q4 24 | -17.4% | — | ||
| Q3 24 | -0.4% | 3.9% | ||
| Q2 24 | 2.2% | 6.3% | ||
| Q1 24 | 1.4% | 5.2% |
每股收益（稀释后）RGENRGR
| Q4 25 | $0.24 | $0.22 | ||
| Q3 25 | $0.26 | $0.10 | ||
| Q2 25 | $0.26 | $-1.05 | ||
| Q1 25 | $0.10 | $0.46 | ||
| Q4 24 | $-0.55 | $0.62 | ||
| Q3 24 | $-0.01 | $0.28 | ||
| Q2 24 | $0.06 | $0.47 | ||
| Q1 24 | $0.04 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $767.6M | $92.5M |
| 总债务越低越好 | $542.2M | — |
| 股东权益账面价值 | $2.1B | $283.8M |
| 总资产 | $2.9B | $342.0M |
| 负债/权益比越低杠杆越低 | 0.26× | — |
8季度趋势，按日历期对齐
现金及短期投资RGENRGR
| Q4 25 | $767.6M | $92.5M | ||
| Q3 25 | $748.7M | $80.8M | ||
| Q2 25 | $708.9M | $101.4M | ||
| Q1 25 | $697.2M | $108.3M | ||
| Q4 24 | $757.4M | $105.5M | ||
| Q3 24 | $784.0M | $96.0M | ||
| Q2 24 | $809.1M | $105.6M | ||
| Q1 24 | $780.6M | $115.3M |
总债务RGENRGR
| Q4 25 | $542.2M | — | ||
| Q3 25 | $537.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $525.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益RGENRGR
| Q4 25 | $2.1B | $283.8M | ||
| Q3 25 | $2.1B | $279.6M | ||
| Q2 25 | $2.1B | $289.3M | ||
| Q1 25 | $2.0B | $321.5M | ||
| Q4 24 | $2.0B | $319.6M | ||
| Q3 24 | $2.0B | $314.9M | ||
| Q2 24 | $2.0B | $321.5M | ||
| Q1 24 | $2.0B | $332.0M |
总资产RGENRGR
| Q4 25 | $2.9B | $342.0M | ||
| Q3 25 | $2.9B | $342.3M | ||
| Q2 25 | $2.9B | $349.5M | ||
| Q1 25 | $2.9B | $379.0M | ||
| Q4 24 | $2.8B | $384.0M | ||
| Q3 24 | $2.8B | $373.5M | ||
| Q2 24 | $2.9B | $376.7M | ||
| Q1 24 | $2.8B | $385.0M |
负债/权益比RGENRGR
| Q4 25 | 0.26× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.7M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $17.6M | $12.3M |
| 自由现金流率自由现金流/营收 | 8.9% | 8.2% |
| 资本支出强度资本支出/营收 | 4.1% | 2.1% |
| 现金转化率经营现金流/净利润 | 1.93× | — |
| 过去12个月自由现金流最近4个季度 | $93.9M | $38.5M |
8季度趋势，按日历期对齐
经营现金流RGENRGR
| Q4 25 | $25.7M | $15.5M | ||
| Q3 25 | $48.1M | $12.9M | ||
| Q2 25 | $28.6M | $14.7M | ||
| Q1 25 | $15.0M | $11.1M | ||
| Q4 24 | $39.2M | $20.0M | ||
| Q3 24 | $49.3M | $9.4M | ||
| Q2 24 | $42.2M | $18.7M | ||
| Q1 24 | $44.7M | $7.3M |
自由现金流RGENRGR
| Q4 25 | $17.6M | $12.3M | ||
| Q3 25 | $43.4M | $7.0M | ||
| Q2 25 | $21.5M | $9.1M | ||
| Q1 25 | $11.4M | $10.0M | ||
| Q4 24 | $33.6M | $16.4M | ||
| Q3 24 | $42.3M | $2.6M | ||
| Q2 24 | $37.4M | $10.1M | ||
| Q1 24 | $36.4M | $5.6M |
自由现金流率RGENRGR
| Q4 25 | 8.9% | 8.2% | ||
| Q3 25 | 23.0% | 5.5% | ||
| Q2 25 | 11.8% | 6.9% | ||
| Q1 25 | 6.8% | 7.4% | ||
| Q4 24 | 19.3% | 11.2% | ||
| Q3 24 | 27.3% | 2.1% | ||
| Q2 24 | 24.3% | 7.7% | ||
| Q1 24 | 24.0% | 4.1% |
资本支出强度RGENRGR
| Q4 25 | 4.1% | 2.1% | ||
| Q3 25 | 2.5% | 4.6% | ||
| Q2 25 | 3.9% | 4.2% | ||
| Q1 25 | 2.1% | 0.8% | ||
| Q4 24 | 3.2% | 2.5% | ||
| Q3 24 | 4.5% | 5.5% | ||
| Q2 24 | 3.1% | 6.6% | ||
| Q1 24 | 5.5% | 1.3% |
现金转化率RGENRGR
| Q4 25 | 1.93× | — | ||
| Q3 25 | 3.23× | 8.15× | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.57× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | 12.70× | 2.27× | ||
| Q1 24 | 21.35× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RGEN
暂无分部数据
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
